Abstract
This chapter illustrates how antibiotic resistance distorts markets for innovative antibiotics in unusual and counterintuitive ways. It also clarifies how proposals to produce a Health Impact Fund (HIF) that rewards companies for the health impacts of their drugs can be used to coordinate effectively global use of antibiotics in a way that manages the threat of resistance. The HIF would foster the development of new high-impact medicines. It would also raise appropriate financial access to new medicines. On the other hand, the antibiotic HIF (aHIF) is very appealing as a global coordination mechanism for antibiotic R&D. It is also scalable throughout the world, despite weak health governance in many countries. It can be stated that the aHIF can serve a key role as a global coordination mechanism for antibiotics, ensuring that this important drug class does not fade away, but continues to serve humanity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
